D.A. Davidson & Co’s Lifecore Biomedical LFCR Stock Holding History

D.A. Davidson & Co’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-2,000	Closed	-$21K	–	2433
2016 Q2	$21K	Hold	2,000	–	–	﹤0.01%	1750
2016 Q1	$21K	Hold	2,000	–	–	﹤0.01%	1696
2015 Q4	$23K	Hold	2,000	–	–	﹤0.01%	1665
2015 Q3	$23K	Buy	2,000 +1,000	+100%	+$13.2K	﹤0.01%	1626
2015 Q2	$14K	Buy	+1,000	New	+$14.4K	﹤0.01%	1779

Other funds holding LFCR

NIMC

NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

TAM

THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return

D.A. Davidson & Co's LFCR Position: Q3 2016 in Review

D.A. Davidson & Co sold out of Lifecore Biomedical (LFCR) in Q3 2016, closing a stake of 2,000 shares — an estimated $21K sold.

D.A. Davidson & Co first reported a position in LFCR in Q2 2015 and held it in 5 quarters. The position peaked at $23K in Q4 2015. 93 funds tracked by Wall St. Rank hold LFCR as of Q3 2016.

D.A. Davidson & Co reported no remaining Lifecore Biomedical position as of Q3 2016 after selling out during the quarter.
D.A. Davidson & Co sold 2,000 Lifecore Biomedical shares in Q3 2016, an estimated $21K.
D.A. Davidson & Co first reported a position in Lifecore Biomedical in Q2 2015 and held it in 5 quarters.
D.A. Davidson & Co's Lifecore Biomedical position peaked at $23K in Q4 2015.
93 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2016.

Based on D.A. Davidson & Co's 13F filing for Q3 2016, filed 14 Nov 2016.